Xu P - Search Results

1

Novel albumin-binding photodynamic agent EB-Ppa for targeted fluorescent imaging guided tumour photodynamic therapy.

Liu H, Yu C, Lyu M, Lyu S, Hu L, Xiao E, Xu P. Liu H, et al. Among authors: xu p. RSC Adv. 2023 Jan 25;13(6):3534-3540. doi: 10.1039/d2ra07380c. eCollection 2023 Jan 24. RSC Adv. 2023. PMID: 36756591 Free PMC article.

2

A rhodol-enone dye platform with dual reaction triggers for specific detection of Cys.

Hu L, Chen Z, Yu C, Zhang J, Zhang H, Xu P, Xiao E. Hu L, et al. Among authors: xu p. J Mater Chem B. 2020 Mar 25;8(12):2438-2442. doi: 10.1039/c9tb02794g. J Mater Chem B. 2020. PMID: 32104831

3

Unsymmetrical cyanine dye via in vivo hitchhiking endogenous albumin affords high-performance NIR-II/photoacoustic imaging and photothermal therapy.

Xu P, Hu L, Yu C, Yang W, Kang F, Zhang M, Jiang P, Wang J. Xu P, et al. J Nanobiotechnology. 2021 Oct 24;19(1):334. doi: 10.1186/s12951-021-01075-0. J Nanobiotechnology. 2021. PMID: 34689764 Free PMC article.

4

Novel albumin-binding photothermal agent ICG-IBA-RGD for targeted fluorescent imaging and photothermal therapy of cancer.

Yu C, Xiao E, Xu P, Lin J, Hu L, Zhang J, Dai S, Ding Z, Xiao Y, Chen Z. Yu C, et al. Among authors: xu p. RSC Adv. 2021 Feb 11;11(13):7226-7230. doi: 10.1039/d0ra09653a. eCollection 2021 Feb 10. RSC Adv. 2021. PMID: 35423244 Free PMC article.

5

A novel NIR-II probe for improved tumor-targeting NIR-II imaging.

Hu C, Guo T, Li H, Xu P, Xiao Y. Hu C, et al. Among authors: xu p. RSC Adv. 2021 Dec 9;11(62):39287-39290. doi: 10.1039/d1ra07135a. eCollection 2021 Dec 6. RSC Adv. 2021. PMID: 35492481 Free PMC article.

6

A novel ratiometric fluorescent probe for rapid detection of hydrogen peroxide in living cells.

Hu L, Liu J, Zhang J, Zhang H, Xu P, Chen Z, Xiao E. Hu L, et al. Among authors: xu p. RSC Adv. 2019 Dec 2;9(67):39532-39535. doi: 10.1039/c9ra07517h. eCollection 2019 Nov 27. RSC Adv. 2019. PMID: 35540638 Free PMC article.

7

Novel albumin-binding multifunctional probe for synergistic enhancement of FL/MR dual-modal imaging and photothermal therapy.

Yu C, Ding Z, Liu H, Ren Y, Zhang M, Liao Q, Luo T, Gao L, Lyu S, Tan H, Hu L, Chen Z, Xu P, Xiao E. Yu C, et al. Among authors: xu p. Front Chem. 2023 Aug 1;11:1253379. doi: 10.3389/fchem.2023.1253379. eCollection 2023. Front Chem. 2023. PMID: 37593108 Free PMC article.

8

In vivo self-assembled albumin nanoparticle elicit antitumor immunity of PD-1 inhibitor by imaging and clearing tumor-associated macrophages.

Yu C, Hu L, Yu Q, Ren Y, Zhang M, Gao L, Lyu S, Wang J, Xiao E, Chen Z, Shang Q, Xu P. Yu C, et al. Among authors: xu p. Front Chem. 2024 Oct 3;12:1469568. doi: 10.3389/fchem.2024.1469568. eCollection 2024. Front Chem. 2024. PMID: 39421608 Free PMC article.

9

Evans blue-modified radiolabeled fibroblast activation protein inhibitor as long-acting cancer therapeutics.

Wen X, Xu P, Shi M, Liu J, Zeng X, Zhang Y, Shi C, Li J, Guo Z, Zhang X, Khong PL, Chen X. Wen X, et al. Among authors: xu p. Theranostics. 2022 Jan 1;12(1):422-433. doi: 10.7150/thno.68182. eCollection 2022. Theranostics. 2022. PMID: 34987657 Free PMC article.

10

Fibroblast Activation Protein-Targeted Radioligand Therapy with 177Lu-EB-FAPI for Metastatic Radioiodine-Refractory Thyroid Cancer: First-in-Human, Dose-Escalation Study.

Fu H, Huang J, Zhao T, Wang H, Chen Y, Xu W, Pang Y, Guo W, Sun L, Wu H, Xu P, Su B, Zhang J, Chen X, Chen H. Fu H, et al. Among authors: xu p, xu w. Clin Cancer Res. 2023 Dec 1;29(23):4740-4750. doi: 10.1158/1078-0432.CCR-23-1983. Clin Cancer Res. 2023. PMID: 37801296 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

11,322 results

Search Page

Filters